Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd > NEWS ... MARBAN RESOURCE

<< Previous

Bullboard Posts

Next >>

Comment by clestoron Sep 07, 2012 9:18am

190 Views

Post# 20330705

RE: NEWS ... MARBAN RESOURCE

I think this is better than expectations.

The estimated global resource (includes oz at Marban, Kierens, & Malartic) is 2,069,000 oz in all categories. The 2009 global resource was 960,222 oz. So, they have increased the global resource estimate by 1.1 mm oz at cost of $11 mm. Aurizon's cost so far is $20 per oz, but they also will spend an additional $9 mm in the upcoming year and then they must make a resource payment. The resource payment will be $38.8 mm if they don't add any more oz via the upcoming $9 mm program.

The PEA will be based on the "In-Pit" resource.

<< Previous

Bullboard Posts

Next >>

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions